ARTIVION, INC. AORT
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
7/9
Piotroski F — financial health
3.05
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $441.3M | $9.8M | $284.2M | $839,000 | $448.2M |
| 2024 | $388.5M | -$13.4M | $248.8M | $11.0M | $276.2M |
| 2023 | $354.0M | -$30.7M | $229.2M | $9.1M | $281.8M |
| 2022 | $313.8M | -$19.2M | $202.5M | -$15.9M | $284.3M |
| 2021 | $298.8M | -$14.8M | $197.5M | -$15.7M | $300.7M |
| 2020 | $253.2M | -$16.7M | $167.8M | $5.0M | $328.7M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.05 (safe)
- Working capital / assets 0.29
- Retained earnings / assets -0.058
- EBIT / assets 0.038
- Equity / liabilities 1.027
Source: SEC EDGAR filings · CIK 0000784199 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.